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Abstract 
Background: Percutaneous dilatational tracheotomy (PDT) has become an established procedure in intensive 
care units (ICU). However, the safety of this method has been under debate given the growing number of critically 
ill patients with high bleeding risk receiving anticoagulation, dual antiplatelet therapy (DAPT) or even a combina-
tion of both, i.e. triple therapy. Therefore, the purpose of this study, including such a high proportion of patients on 
antithrombotic therapy, was to investigate whether PDT in high-risk ICU patients is associated with elevated proce-
dural complications and to analyse the risk factors for bleeding occurring during and after PDT.
Methods: PDT interventions conducted in ICUs at 12 European sites between January 2016 and October 2019 were 
retrospectively analysed for procedural complications. For subgroup analyses, patient stratification into clinically 
relevant risk groups based on anticoagulation and antiplatelet treatment regimens was performed and the predictors 
of bleeding occurrence were analysed.
Results: In total, 671 patients receiving PDT were included and stratified into four clinically relevant antithrombotic 
treatment groups: (1) intravenous unfractionated heparin (iUFH, prophylactic dosage) (n = 101); (2) iUFH (thera-
peutic dosage) (n = 131); (3) antiplatelet therapy (aspirin and/or  P2Y12 receptor inhibitor) with iUFH (prophylactic or 
therapeutic dosage) except for triple therapy (n = 290) and (4) triple therapy (DAPT with iUFH in therapeutic dosage) 
(n = 149). Within the whole cohort, 74 (11%) bleedings were reported to be procedure-related. Bleeding occurrence 
during and after PDT was independently associated with low platelet count (OR 0.73, 95% CI [0.56, 0.92], p = 0.009), 
chronic kidney disease (OR 1.75, 95% CI [1.01, 3.03], p = 0.047) and previous stroke (OR 2.13, 95% CI [1.1, 3.97], 
p = 0.02).
Conclusion: In this international, multicenter study bronchoscopy-guided PDT was a safe and low-complication 
airway management option, even in a cohort of high risk for bleeding on cardiovascular ICUs. Low platelet count, 
chronic kidney disease and previous stroke were identified as independent risk factors of bleeding during and after 
PDT but not triple therapy.
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Introduction
Percutaneous dilatational tracheotomy (PDT) is an 
established procedure for medium to long-term ventila-
tion of ICU patients [9, 12, 27]. PDT is mainly indicated 
in patients with upper respiratory tract obstruction, 
respirator weaning failure, long-term mechanical ven-
tilation due to neurological disorders and to ensure 
patency of airways maintaining proper expectoration of 
bronchial secretion [6, 21, 32]. As a standard of care to 
prevent long-term translaryngeal intubation complica-
tions, PDT has demonstrated its efficacy in preventing 
laryngeal complications such as mucosal erosion, scar-
ring, stenosis, recurrent laryngeal nerve damage, per-
manent vocal cord and upper respiratory tract damage 
[5].
First described by Ciaglia et  al., the most common 
percutaneous dilatational technique allows for proce-
dural application at bedside [4, 20]. Studies have already 
shown a lower incidence of bleeding and infections 
associated with PDT in comparison to open surgical 
tracheotomy [2, 7, 15, 16, 18, 26]. Due to its beneficial 
safety profile, PDT is widely accepted as a low-com-
plication procedure to ensure a safe patient care [27]. 
However, particularly at cardiovascular ICUs critically 
ill patients receiving anticoagulation, dual antiplatelet 
therapy (DAPT) or even a combination of both, i.e. tri-
ple therapy, constitute a significant and steadily grow-
ing proportion of patients today. This development is 
expected to progress, taking into consideration not only 
the global demographic change with aging population, 
but also the growing number of invasive cardiovascular 
interventions with need of intensified and prolonged 
anticoagulant regimens. Moreover, critically ill patients 
often suffer from thrombocytopenia and/or coagula-
tion disorders due to sepsis, organ dysfunctions and 
severity of illness [17]. Several authors suggested that 
PDT may be considered as relatively contraindicated in 
patients with coagulation disorders [19, 23] and there 
are still some relevant questions to answer [9]. Against 
this background, our international, multicenter study 
is the largest investigation to date addressing whether 
PDT can still be regarded as a safe procedure for ICU 
patients even in a steadily growing cohort with high 
risk of bleeding and revealing independent risk factors 
for bleeding during and after PDT.
Methods
Study design and patient selection
This retrospective, multicenter cohort study included 
adult patients (≥ 18  years) undergoing PDT between 
January 2016 and October 2019. These were hospital-
ized at cardiovascular ICUs of 12 clinical sites: Klini-
kum der Ludwig-Maximilians-Universität München 
(Campus Großhadern), Klinikum der Ludwig-Maximil-
ians-Universität München (Campus Innenstadt), Bonn 
University Hospital, Klinikum rechts der Isar der Tech-
nischen Universität München, Heart center Leipzig at 
University of Leipzig, Hannover Medical School, Göt-
tingen University Hospital, Essen University Hospital, 
Heidelberg University Hospital, Münster University 
Hospital, Landesklinikum Wiener Neustadt and Char-
ité University Clinic Berlin. PDT procedures were indi-
cated due to expected prolonged respirator-dependent 
ventilation period of seven days and more. All data 
(i.e. medical history, laboratory analysis, monitoring 
reports, and clinical notes) were taken from the central 
clinical database, with subsequent strict data anonymi-
zation. The clinical data were collected by one senior 
clinician from each site. Validity and integrity of the 
clinical research dataset was controlled by one trained 
ICU physician and one senior ICU physician and by our 
statistical team. Standardized definitions for comorbid-
ities and a data dictionary were provided for each clini-
cal site. Patients were excluded from the analysis even 
if a single value was missing from the dataset. A data 
analysis and statistical plan was written after the data 
were assessed. This is the primary analysis of these data 
which were exclusively collected for present study.
Based on anticoagulation and antiplatelet treatment 
regimen patients were stratified into four clinically rel-
evant antithrombotic treatment groups with a priori 
different risks of bleeding: (1) intravenous unfraction-
ated heparin (iUFH) (prophylactic dosage); (2) iUFH 
(therapeutic dosage); (3) antiplatelet therapy (aspirin 
(100 mg/day) and/or  P2Y12 receptor inhibitor, i.e. clopi-
dogrel (75 mg/day), prasugrel (10 mg/day) or ticagrelor 
(90 mg twice daily)), with iUFH (prophylactic or thera-
peutic dosage) except for triple therapy (n = 290) and 
(4) triple therapy (DAPT including aspirin (100  mg/
day) and a  P2Y12 receptor inhibitor with iUFH in thera-
peutic dosage) (Fig. 1). Of note, all ICU patients receiv-
ing PDT were treated at least with a prophylactic dose 
of heparin, thus there was no treatment group without 
any anticoagulation. In all cases of heparin-induced 
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thrombocytopenia, argatroban was used at equivalent 
doses. In a second analysis, patients were stratified into 
7 antithrombotic subgroups (Additional file 1).
Percutaneous dilatational technique
PDT was performed according to Ciaglia’s technique 
with accompanying bronchoscopy as bedside procedure 
[4, 20] (Fig. 2). Before and throughout PDT, patients were 
ventilated with  FiO2 = 1.0 (biphasic positive airway pres-
sure ventilation). At the beginning, an experienced sen-
ior ICU consultant performed a bronchoscopy-guided 
median puncture of the trachea below the second or 
third tracheal clasp followed by the insertion of a Seld-
inger wire [11, 14]. In most cases a Doppler ultrasound 
examination was previously used to ensure that no blood 
vessels run below the intended puncture site. Dilatation 
of the tracheal accession side was achieved by bougien-
age with different dilators increasing in size (Ciaglia Blue 
Rhino® Set, Cook Medical, Bloomington, USA) along the 
Seldinger guidewire. Subsequently, the tracheal cannula 
was inserted by an introducer. Once tracheostomy tube 
cuff was inflated and correct localization of the tracheal 
cannula within the trachea was confirmed by bronchos-
copy, the tracheal cannula was connected to the respira-
tory system. Finally, repeated bronchoscopic position 
control of the tracheal cannula and post-interventional 
exclusion of pneumothorax by thoracic radiograph were 
performed. For anaesthesia, all patients received fenta-
nyl (15–50  µg/kg) or sufentanil (5–20  µg/kg), propofol 
(1.0–2.5  mg/kg KG) and cisatracurium as short-acting 
muscle relaxant (0.10–0.15 mg/kg). In a timeframe of 4 h 
pre- and post-procedure, anticoagulation with unfrac-
tionated heparin was suspended as standard precaution-
ary measure.
Ethics approval
The study was conducted in accordance with the Dec-
laration of Helsinki and the institutional and national 
guidelines and was approved by the local ethics boards 
(LMU ethics committee reference number: 19–592-KB). 
The university hospital’s institutional ethic committee 
waived the need for informed consent because our obser-
vational retrospective study did not modify existing diag-
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Antiplatelet therapy (aspirin 
and/or P2Y12 receptor 
inhibitor) with intravenous 
unfractionated heparin
(prophylactic or therapeutic 
dosage) except for triple 
therapy (n = 290)
Fig. 1 Study flowchart. Flow diagram depicting patient selection
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in individual charts on hospital servers, which were bio-
metrically protected, and the extracted data were ana-
lysed strictly anonymously.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism® (version 8.0, GraphPad Software Inc.), SPSS® 
(version 25.0, SPSS Inc.), and R® (version 3.5.2). Kolmog-
orov–Smirnov test, D’Agostino–Pearson omnibus test, 
q–q plots and histograms were used to test the normal-
ity of data distribution. Normally distributed continuous 
variables were reported as a mean with standard devia-
tion and non-normally distributed continuous variables 
as a median with interquartile ranges (25th and 75th 
percentile). To compare two groups, an independent 
t-test for normally distributed continuous variables and 
the Mann–Whitney U test for non-normally distributed 
continuous variables were used. Categorical variables 
were reported as absolute numbers and percentages. 
To compare groups, an exact Fisher’s test was utilized. 
All tests were 2-tailed, and p-values < 0.05 were consid-
ered as significant. We used logistic regression models 
to determine predictors for bleeding during and after 
PDT. Factors that were suggested to be significant in the 
univariable analyses, as indicated by p-values < 0.2, were 
included in the multivariable model. No statistical power 
calculation was conducted prior to the study, and the 
sample size was based on the available data. Only our sta-
tistical team had access to the raw data.
Results
Patient baseline characteristics
During the study period, a total of 695 patients, receiv-
ing PDT at ICUs of 12 clinical sites, were evaluated. Of 
these, 24 were excluded due to incomplete data. Patient 
distribution across the different antithrombotic treat-
ment groups were as follows: (1) iUFH (prophylactic 
dosage), n = 101 (15%); (2) iUFH (therapeutic dosage), 
Fig. 2 Percutaneous dilatational tracheotomy according to Ciaglia’s technique. Percutaneous dilatational tracheotomy according to Ciaglia’s 
technique with accompanying bronchoscopy: first, a colour Doppler ultrasound examination may be performed to ensure that no blood vessels 
run below the intended puncture site. After administration of local anaesthesia (A), median puncture of the trachea below the second or third 
tracheal clasp under bronchoscopic visualization and insertion of a Seldinger wire (B) is performed. The Seldinger guidewire is used for bougienage 
with different dilators (Ciaglia Blue Rhino® Set, Cook Medical) (C) under bronchoscopic visualization (D). Subsequently, the tracheal cannula 
is inserted along an introducer and—after bronchoscopy-guided confirmation of correct localization of the cannula within the trachea and 
subsequent cuff inflation—connected to the respiratory system (E). Final bronchoscopic position control of the tracheal cannula (F)
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n = 131 (19%); (3) antiplatelet therapy and/or P2Y12 
receptor inhibitor with iUFH (prophylactic or therapeu-
tic dosage) except for triple therapy, n = 290 (43%) and 
(4) triple therapy, n = 149 (22%) (Fig. 1). The overall mean 
age across all treatment groups was 65 ± 14  years, with 
66% being male. The majority of patients were admitted 
at the hospital due to acute myocardial infarction (23%), 
shock (20%) and acute respiratory failure (18%). PDT was 
performed 7 to 10  days after primary intubation. Blood 
analysis at the day of PDT showed haemoglobin (Hb) lev-
els of 9.3 ± 1.5 g/dl, activated partial thromboplastin time 
(aPTT) values of 43 ± 18  s, mean international normal-
ized ratio (INR) values of 1.2 ± 0.3 and platelet counts of 
223 ± 134 g/l. A comprehensive overview of clinically rel-
evant information is shown in Table 1.
Antithrombotic treatment group and procedure‑related 
complications
Across all treatment groups, low incidence rates for pro-
cedure-related complications were observed (Table  2). 
Within the whole cohort, 26 (4%) patients were reported 
to suffer from intraprocedural and 48 (7%) from postpro-
cedural bleeding. In almost all cases haemorrhage was 
associated with skin bleeding from the entry site and 
could easily be treated with minimally invasive stitch-
ing. None of the bleeding incidents required surgical 
Table 1 Baseline characteristics of different antithrombotic treatment groups with a total of 671 patients included between January 
2016 and October 2019 at ICUs of 12 clinical sites: (1) intravenous unfractionated heparin (iUFH, prophylactic dosage), (2) iUFH 
(therapeutic dosage), (3) antiplatelet therapy (aspirin (100 mg/day) and/or P2Y12 receptor inhibitor, i.e. clopidogrel (75 mg/day), 
prasugrel (10 mg/day) or ticagrelor (90 mg twice daily)) with iUFH (prophylactic or therapeutic dosage) except for triple therapy and 
(4) triple therapy (DAPT including aspirin (100 mg/day) and a P2Y12 receptor inhibitor with iUFH in therapeutic dosage)
All displayed laboratory values were recorded on the day of PDT 4 h prior to procedure. ARDS acute respiratory distress syndrome, COPD chronic obstructive 
pulmonary disease, INR International Normalized Ratio, aPTT activated Partial Thromboplastin Time, SD standard deviation








(III) Aspirin and/or P2Y12 
receptor inhibitor with 
Heparin (prophylactic or 
therapeutic dosage) except 
for triple therapy (n = 290)
(IV) DAPT with heparin 
(therapeutic dosage) (triple 
therapy) (n = 149)
Overall
(n = 671)
Age [years] mean ± SD 55 ± 16 64 ± 13 66 ± 12 70 ± 12 65 ± 14
Gender [male] n (%) 56 (55) 80 (61) 208 (72) 99 (66) 444 (66)
Body mass index [kg/m2] 
mean ± SD
26.02 ± 5.67 27.87 ±  + 5.39 27.16 ±  + 5.27 26.99 ± 4.68 27.08 ± 5.25
Reason for hospitalization
 Acute respiratory failure 
(ARDS, COPD, pneumonia) 
n (%)
38 (38) 32 (24) 43 (15) 6 (4) 119 (18)
 Sepsis n (%) 12 (12) 11 (8) 9 (3) 7 (5) 39 (6)
 Acute myocardial infarciation 
n (%)
0 (0) 0 (0) 78 (27) 77 (52) 155 (23)
 Shock (cardiogenic/septic/ 
hemorrhagic) n (%)
28 (28) 34 (26) 48 (17) 23 (15) 133 (20)
Others n (%) 23 (23) 54 (41) 112 (39) 36 (24) 225 (34)
Hypertension n (%) 49 (49) 78 (60) 212 (73) 116 (78) 455 (68)
Diabetes mellitus n (%) 15 (15) 38 (29) 89 (31) 55 (37) 197 (29)
Current smoker n (%) 19 (19) 34 (26) 101 (35) 42 (28) 196 (29)
Chronic kidney disease n (%) 24 (24) 54 (41) 90 (31) 50 (34) 219 (33)
Previous stroke n (%) 5 (5) 14 (11) 42 (14) 21 (14) 82 (12)
Atrial fibrillation n (%) 8 (8) 90 (69) 107 (37) 105 (70) 310 (46)
Aspirin n (%) 0 0 266 (92) 149 (100) 415 (62%)
P2Y12 inhibitor n (%) 0 0 138 (48) 149 (100) 287 (43%)
Creatinine [mg/dl] mean ± SD 1.38 ± 0.87 1.63 ± 0.95 1.60 ± 0.94 1.52 ± 0.85 1.57 ± 0.95
Hemoglobin [g/dl] mean ± SD 9.26 ± 1.55 9.28 ± 1.75 9.28 ± 1.46 9.34 ± 1.33 9.29 ± 1.51
Platelet count [G/l] mean ± SD 216 ± 150 222 ± 131 212 ± 131 249 ± 130 223 ± 134
INR mean ± SD 1.21 ± 0.42 1.23 ± 0.33 1.17 ± 0.30 1.24 ± 0.25 1.20 ± 0.32
aPTT [s] mean ± SD 37.99 ± 15.68 48.65 ± 22.96 39.10 ± 14.15 47.66 ± 16.82 42.68 ± 17.58
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intervention. In a total of nine cases, persistent subcuta-
neous bleeding from the entry site necessitated a short-
term change to larger tracheal cannula. In two cases 
there was relevant hypoxia, in one case an intraproce-
dural venous bleeding caused by the Seldinger guidewire 
requiring resuscitation. In two other cases, the proce-
dure resulted in resuscitation as a result of anaesthesia-
induced hypotension in critically ill patients.
Complications related to PDT included tracheal car-
tilage fracture in 29 (4%) cases. An accidental cannula 
dislocation occurred in 13 (2%), an accidental endotra-
cheal tube dislocation during PDT procedure in 8 
(1%) patients, all of which could be handled through 
bronchoscopy-guided repositioning or repeated laryn-
goscopy-guided intubation. An overview of all other 
PDT-related complications is given in Table  2. Impor-
tantly, there were no significant differences between the 
antithrombotic treatment groups regarding PDT-related 
complications (Table 2) and interestingly, even high BMI 
values (> 30  kg/m2) were not associated with consider-
ably higher incidence rates of procedural complications 
(Additional file 1: Table S1).
Predictors of bleeding during and after PDT
The results of the univariable and multivariable anal-
ysis are summarized in Table  3. The multivariable 
analysis was based on a logistic regression model and 
revealed low platelet count (OR 0.73, 95% CI [0.56, 0.92], 
p = 0.009), chronic kidney disease (OR 1.75, 95% CI [1.01, 
3.03], p = 0.047) and previous stroke (OR 2.13, 95% CI 
Table 2 Procedural related complications during and after PDT differentiated by treatment group
p-values < 0.05 were considered as significant; ns non-significant
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5 (5) 4 (3) 13 (4) 4 (3) 26 (4) ns
Postprocedural bleeding 
n (%)
9 (9) 9 (7) 19 (7) 11 (7) 48 (7) ns
Intra-/postproceddural 
bleeding n (%)
14 (14) 13 (10) 32 (11) 15 (10) 74 (11) ns
Intra-/postproceddural 
pneumothorax n (%)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) ns
Intraprocedural accidental 
cannula dislocation n (%)
3 (3) 7 (5) 2 (1) 1 (1) 13 (2) ns
Intraprocedural accidental 
tubus dislocation n (%)
0 (0) 2 (2) 4 (1) 2 (1) 8 (1) ns
Postprocedural tracheocuta-
neous fistula n (%)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) ns
Postprocedural infection 
n (%)
1 (1) 0 (0) 4 (1) 0 (0) 5 (1) ns
Postprocedural granulation 
at the tracheostoma n (%)
1 (1) 2 (2) 0 (0) 1 (1) 4 (1) ns
Postprocedural wound heal-
ing n (%)
1 (1) 0 (0) 1 (1) 0 (0) 2 (0) ns
Intraprocedural  O2 desatura-
tion n (%)
2 (2) 1 (1) 7 (2) 0 (0) 10 (1) ns
Intraprocedural hypotension 
n (%)
5 (5) 3 (2) 17 (6) 5 (3) 30 (4) ns
Intraprocedural cardiac 
arrhythmia n (%)
1 (1) 0 (0) 0 (0) 0 (0) 1 (0) ns
Intraprocedural fracture of 
tracheal cartilage n (%)
1 (1) 9 (7) 13 (4) 6 (4) 29 (4) ns
Intraprocedural resuscitation 
n (%)
1 (1) 0 (0) 4 (1) 0 (0) 5 (1) ns
Intra/postprocedural death 
n (%)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) ns
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[1.1, 3.97], p = 0.02) to be independently associated with 
bleeding during and after PDT. Different antithrombotic 
treatment regimens including triple therapy were not 
associated with bleeding risk.
Discussion
In the current study, we provide strong evidence to 
revoke the perception of intensified antithrombotic 
therapy as contraindication for PDT. Despite the inher-
ently high risk of bleeding in this cohort, PDT could be 
performed efficiently, and procedure-related complica-
tion rate was very low at all. This is a remarkable finding, 
also in light of 149 (22%) patients undergoing PDT even 
on triple therapy. Overall, no case of death was directly 
attributed to PDT procedure and there were only 5 (0.7%) 
procedure-related resuscitations, all of which could be 
ended with ROSC and without permanent patient dam-
age. Considering the findings of this study, we conclude 
that potential complications of long-term translaryngeal 
intubation outweigh the low PDT-related complication 
rate. Interestingly, clinical practice showed that mild 
bleeding at the tracheal cannula incision site can be eas-
ily controlled or prevented with a minimally invasive 
suture technique consisting of two single-head sutures at 
the incision point next to the tracheal cannula [22]. For 
this reason, this technique may be considered to be rou-
tinely used in all PDTs. Importantly, bronchoscopy guid-
ance, combined with optional pre-procedural ultrasound, 
should be routinely performed to better determine the 
exact needle insertion site and tracheostomy positioning 
to increase safety during the procedure [9].
The present international, multicenter study provides 
the most comprehensive safety evaluation of current 
PDT practice in the largest cohort of high bleeding risk 
patients on antithrombotic therapy. The results fur-
ther underline the superiority of PDT in procedural 
safety—in particular also regarding bleeding complica-
tions—as compared with surgical tracheotomy [1, 11, 
16, 25]. Based on present investigation, PDT, if correctly 
indicated and performed, can be recommended as a safe 
method of securing airway, even in a cohort with high 
risk of bleeding resulting from anticoagulation, DAPT 
or a combination of both. Despite their inherent risk to 
provoke hemorrhage compared to physiologic hemosta-
sis, no antithrombotic treatment regimen considered in 
our study was an independent risk factors for bleeding 
Table 3 Predictors of bleeding occurrence during and after PDT
Logistic regression models were used to determine important predictors for bleeding during and after PDT. Factors with a P-value < 0.2 in the univariable analyses 
were included in the multivariable model. P-values < 0.05 were considered significant. OR Odds ratio, 95% CI 95% confidence interval, INR International Normalized 
Ratio, aPTT activated Partial Thromboplastin Time
Attribute Univariate analysis Multivariate analysis
OR [95% CI] p‑value OR [95% CI] p‑value
Age (per year) 1 [0.99, 1.02] 0.61
Gender 0.75 [0.41, 1.32] 0.34
Body mass index (per kg/m2) 1.02 [0.98, 1.07] 0.32
Hypertension 1.45 [0.84, 2.6] 0.19 1.13 [0.63, 2.09] 0.683
Diabetes mellitus 1.01 [0.58, 1.71] 0.97
Current smoker 0.56 [0.3, 1.01] 0.07 0.54 [0.28, 0.98] 0.051
Chronic kidney disease 2.2 [1.34, 3.62] 0.002 1.75 [1.01, 3.03] 0.047
Previous Stroke 2.35 [1.24, 4.26] 0.01 2.13 [1.1, 3.97] 0.02
Atrial fibrillation 1.08 [0.66, 1.77] 0.76
Heparin (prophylactic dosage) 0.99 [0.46, 1.93] 0.99
Heparin (therapeutic dosage) 0.92 [0.47, 1.68] 0.79
Aspirin and heparin (prophylactic dosage) 0.94 [0.27, 2.43] 0.9
Aspirin and heparin (therapeutic dosage) 0.86 [0.4, 1.67] 0.68
P2Y12 receptor and heparin (therapeutic dosage) 1.22 [0.28, 3.65] 0.76
DAPT with heparin (prophylactic dosage) 1.11 [0.56, 2.04] 0.75
Triple-therapy 0.93 [0.49, 1.66] 0.82
Creatinine (per mg/dl) 1.23 [0.97, 1.55] 0.08 1.06 [0.79, 1.38] 0.698
Hemoglobin (per g/dl) 0.92 [0.77, 1.08] 0.32
Platelet count (per G/l) 0.7 [0.55, 0.88] 0.003 0.73 [0.56, 0.92] 0.009
INR 1.59 [0.8, 2.85] 0.14 0.61 [0.13, 1.75] 0.438
aPTT (per s) 1.01 [0.99, 1.02] 0.32
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complications. Current proof of safety is accompanied by 
many well documented complementing benefits of PDT 
such as improvement of patient comfort, oral hygiene 
and nurse care, reduced need for sedation and analgesia, 
spontaneous closure of the wound after decannulation 
and barely visible scar, reduced work of breathing, short-
ened weaning period from the respirator as well as over-
all shortened ICU stay [3, 8, 10, 13, 24, 28]. Of note, PDT 
was performed 7 to 10 days after primary intubation. Tri-
als comparing earlier and later tracheostomy found no 
difference in hospital length of stay, ICU length of stay 
and overall mortality and meta-analyses showed that 
timing was not associated with all-cause ICU mortality 
or 1-year mortality [30, 31, 33]. Nevertheless, the ques-
tion of the optimal time for tracheostomy still remains 
unanswered and further prospective randomized trials 
are needed to answer this question [9].
However, a systematic registration of independent risk 
factors for bleeding complications, namely chronic kid-
ney disease, previous stroke and platelet count, could 
enable further improvement of PDT procedure and out-
come. Notably, this is the first time that these risk factors 
have been identified. Consequent optimization of the 
attributes mentioned above, such as timely correction 
of low platelet counts under consideration of contrain-
dications of platelet transfusion and its associated risk 
of thrombosis, may contribute to a further reduction of 
bleeding risk. Additionally, in order to identify patients 
with coagulation disorders, including platelet dysfunc-
tions, the establishment of extended platelet function and 
coagulation testing, i.e. ADP-induced platelet aggrega-
tion [29], may be discussed before performing PDT pro-
cedure. Furthermore, mentioned predictors allow better 
identification of patients with an a priori increased risk 
of bleeding, for whom close monitoring with optimal 
awareness and readiness for complication management is 
required.
An additional interest of this study was to evaluate the 
role of highly prevalent obesity for PDT-related com-
plications. In early investigations, obesity (BMI ≥ 30) 
increased the procedure-related complication rate up 
to 15%, comparing to 8% in patient with BMI < 30 [21]. 
Contrary to that, we did not find a significant increase 
in PDT-related complications in patients with high BMI 
values in accordance with more recent studies [27]. Con-
sequently, the findings from our investigation did not 
regard obesity as general contraindication for perform-
ing PDT, although anatomical challenges caused by an 
increased amount of pre-tracheal tissue for example as 
well as derangements that may occur during airway man-
agement should be considered thoroughly in this patient 
group to minimize the risk of procedure-related compli-
cations as previously described [27].
Limitations
The limited sample size of events reduces the reproduc-
ibility and reliability of the observations. Furthermore, 
due to the retrospective nature of the present investiga-
tion, there are limitations inherent to observational stud-
ies resulting mainly from a lack of randomization and 
blinding, namely unmeasured confounders, selection 
bias, incomplete datasets, and the lack of strict protocols 
covering all aspects of care. With a decentralized inter-
national, multicenter approach, we aimed to limit the 
potential influence of single centre bias.
Conclusions
The present study, based on the analysis of 671 ICU 
patients, showed that bronchoscopy-guided PDT is a 
safe procedure for airway management in ICU patients, 
even in the subpopulation of patients treated with dual 
antiplatelet therapy and therapeutic anticoagulation (tri-
ple therapy). Chronic kidney disease, previous stroke 
and low platelet count were independent risk factors for 
PDT-related bleeding complications.
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